THBD and blood coagulation disease: For example, measurements of triggering receptor expressed on myeloid cells (TREM) could be used to identify candidates most likely to respond to anti-TREM therapies, or patients with coagulopathy or specific inflammatory patterns could be selected for treatments like thrombomodulin or activated protein C. However, challenges remain, including the need for more rapid tools that can be used at the bedside to inform real-time treatment decisions given the rapidly evolving nature of the sepsis response.